Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours ยท Estimated delivery Aug 27 - Sep 1
The compound remains in Phase 3 clinical trials with FDA approval expected in 2026-2027
This compounded injection is available exclusively through our 503A compounding pharmacy pursuant to a patient-specific prescription
Injecting contaminated solution introduces these organisms directly into subcutaneous tissue, potentially causing: Localized injection site reactions (redness, swelling, warmth) Abscess formation requiring medical drainage Cellulitis (spreading skin infection) In rare cases, systemic infection The risk is highest for vials that are significantly past their BUD, have been stored improperly, or have been punctured many times
most participants (92.5%, n =482) completed the trial, with 39 participants prematurely discontinuing treatment
US$ 23.49
US$ 21.54
US$ 27.17
